Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. More Details
Flawless balance sheet with solid track record.
Share Price & News
How has Feng Chi Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6744 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 6744's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 6744 underperformed the TW Healthcare industry which returned 15.2% over the past year.
Return vs Market: 6744 underperformed the TW Market which returned 44.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Feng Chi Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StIs Feng Chi Biotech Corp.'s (GTSM:6744) Recent Performance Tethered To Its Attractive Financial Prospects?
4 months ago | Simply Wall StFeng Chi Biotech Corp. (GTSM:6744) Is Yielding 3.3% - But Is It A Buy?
10 months ago | Simply Wall StFeng Chi Biotech Corp.'s (GTSM:6744) Share Price Could Signal Some Risk
Is Feng Chi Biotech undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 6744 (NT$27.8) is trading below our estimate of fair value (NT$56.55)
Significantly Below Fair Value: 6744 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 6744 is good value based on its PE Ratio (16.9x) compared to the TW Healthcare industry average (17.3x).
PE vs Market: 6744 is good value based on its PE Ratio (16.9x) compared to the TW market (17.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6744's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6744's PB Ratio (1.9x) is in line with the TW Healthcare industry average.
How is Feng Chi Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Feng Chi Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Feng Chi Biotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6744 has high quality earnings.
Growing Profit Margin: 6744's current net profit margins (14.2%) are higher than last year (10%).
Past Earnings Growth Analysis
Earnings Trend: 6744's earnings have grown by 14.7% per year over the past 5 years.
Accelerating Growth: 6744's earnings growth over the past year (46%) exceeds its 5-year average (14.7% per year).
Earnings vs Industry: 6744 earnings growth over the past year (46%) exceeded the Healthcare industry -2.6%.
Return on Equity
High ROE: 6744's Return on Equity (11.3%) is considered low.
How is Feng Chi Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: 6744's short term assets (NT$261.6M) exceed its short term liabilities (NT$56.4M).
Long Term Liabilities: 6744's short term assets (NT$261.6M) exceed its long term liabilities (NT$2.6M).
Debt to Equity History and Analysis
Debt Level: 6744 is debt free.
Reducing Debt: 6744 has not had any debt for past 5 years.
Debt Coverage: 6744 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 6744 has no debt, therefore coverage of interest payments is not a concern.
What is Feng Chi Biotech current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 6744's dividend (4.14%) is higher than the bottom 25% of dividend payers in the TW market (2.06%).
High Dividend: 6744's dividend (4.14%) is low compared to the top 25% of dividend payers in the TW market (5.01%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether 6744's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if 6744's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (69.7%), 6744's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Feng Chi Biotech has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Feng Chi Biotech Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Feng Chi Biotech Corp.
- Ticker: 6744
- Exchange: TPEX
- Founded: NaN
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: NT$428.120m
- Shares outstanding: 15.40m
- Website: https://www.fcbiotech.com.tw
Number of Employees
- Feng Chi Biotech Corp.
- 1, No.5, Shaoxing North Street
- 5th Floor
Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services....
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/11 08:35|
|End of Day Share Price||2021/06/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.